TriangleNCT00602667 · OUTCOME
Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percent Probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From date on treatment to date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment
What was measured
Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. Eligible medulloblastoma patients who received any methotrexate and had molecularly confirmed medulloblastoma are included in this analysis. Five patients were excluded as 3 had no archival tissue available and 2 were found to not be medulloblastoma by methylation profile.
Analysis population: Eligible patients with molecularly confirmed medulloblastoma (n=76) were included. PFS estimates are reported by methylation subgroup and risk group. There were no low-risk group 3 or group 4 patients.
Groups in this outcome
Low-risk SHH Patients
Sonic hedgehog (SHH) medulloblastoma subgroup patients in the low-risk group
Intermediate-risk SHH Patients
Sonic hedgehog (SHH) medulloblastoma subgroup patients in the intermediate-risk group
High-risk SHH Patients
Sonic hedgehog (SHH) medulloblastoma subgroup patients in the high-risk group
Low-risk Group 3 Patients
Group 3 (G3) medulloblastoma subgroup patients in the low-risk group
Intermediate-risk Group 3 Patients
Group 3 medulloblastoma subgroup patients in the intermediate-risk group
High-risk Group 3 Patients
Group 3 medulloblastoma subgroup patients in the high-risk group
Low-risk Group 4 Patients
Group 4 (G4) medulloblastoma subgroup patients in the low-risk group
Intermediate-risk Group 4 Patients
Group 4 (G4) medulloblastoma subgroup patients in the intermediate-risk group
High-risk Group 4 Patients
Group 4 medulloblastoma subgroup patients in the high-risk group
| Group | Source count |
|---|---|
| Low-risk SHH Patients | 23 |
| Intermediate-risk SHH Patients | 8 |
| High-risk SHH Patients | 11 |
| Low-risk Group 3 Patients | 0 |
| Intermediate-risk Group 3 Patients | 13 |
| High-risk Group 3 Patients | 11 |
| Low-risk Group 4 Patients | 0 |
| Intermediate-risk Group 4 Patients | 8 |
| High-risk Group 4 Patients | 2 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Low-risk SHH Patients | 73.9 | Not reported | 56.5 | 91.3 | Not reported |
| Intermediate-risk SHH Patients | 50.0 | Not reported | 19.0 | 81.0 | Not reported |
| High-risk SHH Patients | 54.5 | Not reported | 27.3 | 81.7 | Not reported |
| Intermediate-risk Group 3 Patients | 30.8 | Not reported | 8.5 | 53.1 | Not reported |
| High-risk Group 3 Patients | 9.1 | Not reported | 0.0 | 21.1 | Not reported |
| Intermediate-risk Group 4 Patients | 62.5 | Not reported | 31.9 | 93.1 | Not reported |
| High-risk Group 4 Patients | 50.0 | Not reported | 1.0 | 99.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 56.5
- upper Limit
- 91.3
- value
- 73.9
- group Id
- OG001
- lower Limit
- 19.0
- upper Limit
- 81.0
- value
- 50.0
- group Id
- OG002
- lower Limit
- 27.3
- upper Limit
- 81.7
- value
- 54.5
- group Id
- OG004
- lower Limit
- 8.5
- upper Limit
- 53.1
- value
- 30.8
- group Id
- OG005
- lower Limit
- 0.0
- upper Limit
- 21.1
- value
- 9.1
- group Id
- OG007
- lower Limit
- 31.9
- upper Limit
- 93.1
- value
- 62.5
- group Id
- OG008
- lower Limit
- 1.0
- upper Limit
- 99.0
- value
- 50.0
- denoms
- counts
- group Id
- OG000
- value
- 23
- group Id
- OG001
- value
- 8
- group Id
- OG002
- value
- 11
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 13
- group Id
- OG005
- value
- 11
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 8
- group Id
- OG008
- value
- 2
- units
- Participants
- description
- Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. Eligible medulloblastoma patients who received any methotrexate and had molecularly confirmed medulloblastoma are included in this analysis. Five patients were excluded as 3 had no archival tissue available and 2 were found to not be medulloblastoma by methylation profile.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Sonic hedgehog (SHH) medulloblastoma subgroup patients in the low-risk group
- id
- OG000
- title
- Low-risk SHH Patients
- description
- Sonic hedgehog (SHH) medulloblastoma subgroup patients in the intermediate-risk group
- id
- OG001
- title
- Intermediate-risk SHH Patients
- description
- Sonic hedgehog (SHH) medulloblastoma subgroup patients in the high-risk group
- id
- OG002
- title
- High-risk SHH Patients
- description
- Group 3 (G3) medulloblastoma subgroup patients in the low-risk group
- id
- OG003
- title
- Low-risk Group 3 Patients
- description
- Group 3 medulloblastoma subgroup patients in the intermediate-risk group
- id
- OG004
- title
- Intermediate-risk Group 3 Patients
- description
- Group 3 medulloblastoma subgroup patients in the high-risk group
- id
- OG005
- title
- High-risk Group 3 Patients
- description
- Group 4 (G4) medulloblastoma subgroup patients in the low-risk group
- id
- OG006
- title
- Low-risk Group 4 Patients
- description
- Group 4 (G4) medulloblastoma subgroup patients in the intermediate-risk group
- id
- OG007
- title
- Intermediate-risk Group 4 Patients
- description
- Group 4 medulloblastoma subgroup patients in the high-risk group
- id
- OG008
- title
- High-risk Group 4 Patients
- param Type
- NUMBER
- population Description
- Eligible patients with molecularly confirmed medulloblastoma (n=76) were included. PFS estimates are reported by methylation subgroup and risk group. There were no low-risk group 3 or group 4 patients.
- reporting Status
- POSTED
- time Frame
- From date on treatment to date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment
- title
- Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup
- type
- PRIMARY
- unit Of Measure
- Percent Probability
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice